Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.
about
Predicting mortality in patients with acute heart failure: Role of risk scoresClinical adoption of prognostic biomarkers: the case for heart failureEarly management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working groupRecent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapiesState of the Art: Newer biomarkers in heart failureCan biomarkers help to diagnose early heart failure with preserved ejection fraction?Right Atrium Volume Index in Patients with Secondary Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease.Galectin 3 and incident atrial fibrillation in the community.Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo StudyClinical Correlates and Prognostic Value of Plasma Galectin-3 Levels in Degenerative Aortic Stenosis: A Single-Center Prospective Study of Patients Referred for Invasive TreatmentUsefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure.Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure.Galectin-3 and left ventricular reverse remodelling after surgical mitral valve repair.Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study.Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumabBiomarkers in cardiology--part 1--in heart failure and specific cardiomyopathiesAssessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart FailureGalectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis.Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group.Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?Changes in the myocardial interstitium and contribution to the progression of heart failure.Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patientsMid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve.Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.Galectin-3: A Link between Myocardial and Arterial Stiffening in Patients with Acute Decompensated Heart Failure?Serum Galectin and Renal Dysfunction in ST-Segment Elevation Myocardial Infarction.Galectin-3 Is Elevated and Associated With Adverse Outcomes in Patients With Single-Ventricle Fontan Circulation.Galectin 3 complements BNP in risk stratification in acute heart failure.Role of galectin-3 and plasma B type-natriuretic peptide in predicting prognosis in discharged chronic heart failure patients.Elevated galectin-3 precedes the development of CKDAcute heart failure: patient characteristics and pathophysiology.Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.
P2860
Q26771109-A16B143D-7C45-4A15-9803-AD9437D4E3FEQ26863716-4F3F77A4-E195-4550-9200-47D1994291F7Q27000455-4A502596-F77C-4B8B-ABC7-B4D61F8CAF79Q27002436-86A3F78B-0BD8-4E78-9C3B-7EC88D185651Q27027899-B0FFF1C3-7832-4B5F-A2EC-2FE7813CE8A7Q28087822-217F75D0-4E0C-44FE-B95C-862F6DC2F24BQ30385148-A5C061CD-54D2-44FD-B3FD-FE8C60198F89Q33555143-D40C643E-8848-47A9-8693-67A33D0E3B73Q33577541-F9FB1885-D047-453F-892E-D1E3AADA4177Q33754895-E986BB55-89F2-4D9F-BEF2-F2F11E9831A8Q33912126-DEEE812C-DBB3-4349-9C56-AEB47B071AACQ34102031-95E0A0C8-8F18-45C3-AFCC-7DE7EC6251B2Q34338521-F6304AAC-B725-4FA4-892D-C53AFACFC94BQ34528187-19AF6B09-4DA4-447F-BF55-2C45C988E332Q34622450-192A589C-8A96-42EC-AE59-029CE7707585Q34855776-E1F41E51-453B-48F3-A414-864A108A73F6Q34914470-9FE7D71F-1117-4F78-B5F1-07F44E69A08DQ34997796-E6230EFE-48BA-43C0-AA66-B542CA3E1EA5Q35026202-153CA301-27BD-4678-BA31-777A4B1F4663Q35057622-17AC54D7-4871-4E84-9A99-34A4365D33DAQ35109460-07F3A111-0C75-46E1-AF6D-53456D1B273EQ35206146-3EA3D1E0-ECD7-416E-A22D-247ADC012B96Q35286926-79C1C4D5-BC40-4B82-B4EF-E7AE765850FDQ35582221-90464377-706E-4C00-95B6-A03E3FDC2431Q35680958-264F89DA-7E04-45D9-ACA2-B9D0C5B7122CQ36035702-4D898D3C-4449-4479-A418-CB5DD10E3B15Q36181301-96E363BA-C256-4C2A-B6B1-833F8B2BD893Q36203596-63645696-2212-4610-AB89-15949066E2B3Q36244494-5E7DD332-D1CA-4DFF-9321-E73A7E5C12FFQ36439679-A28827B1-1045-4670-8887-52CCD045CEE1Q36522700-D4FE0A2A-7DBA-4E87-8DF3-097CB743C162Q36611468-0C69E02B-8C19-4444-9A90-298BA8BD2716Q36627699-8D4E4D61-AD77-45DE-9E73-16A50A51492CQ36877769-B0085FF9-5AFD-4944-AF12-D9D142E700C6Q36917873-308DF70E-3AFF-4EE6-BEAB-07399DFA81CFQ37077973-CF355685-73C9-4576-9D38-660E5133C4A8Q37119904-76CD746A-5AA9-4D13-90FB-E81036C22BAEQ37297364-DB8C9D9B-A0AC-4B0E-A82F-E4C187A86CB1Q37595342-3B3C8209-CDE3-40D9-BE4B-EDF360E038B4Q37631139-0720924B-169B-4998-AE21-CCCBBA6A821B
P2860
Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Galectin-3, cardiac structure ...... y decompensated heart failure.
@ast
Galectin-3, cardiac structure ...... y decompensated heart failure.
@en
Galectin-3, cardiac structure ...... y decompensated heart failure.
@nl
type
label
Galectin-3, cardiac structure ...... y decompensated heart failure.
@ast
Galectin-3, cardiac structure ...... y decompensated heart failure.
@en
Galectin-3, cardiac structure ...... y decompensated heart failure.
@nl
prefLabel
Galectin-3, cardiac structure ...... y decompensated heart failure.
@ast
Galectin-3, cardiac structure ...... y decompensated heart failure.
@en
Galectin-3, cardiac structure ...... y decompensated heart failure.
@nl
P2093
P2860
P356
P1476
Galectin-3, cardiac structure ...... y decompensated heart failure.
@en
P2093
Annabel A Chen-Tournoux
Michael H Picard
Ravi V Shah
Roland R J van Kimmenade
P2860
P304
P356
10.1093/EURJHF/HFQ091
P577
2010-06-05T00:00:00Z